For the quarter ending 2025-09-30, DMAC had -$783K decrease in cash & cash equivalents over the period. -$6,566K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total operating expenses, excluding share-based compensation | 8,017 | - |
| Total share-based compensation | 1,016 | - |
| Operating loss | -9,033 | - |
| Interest income | 440 | - |
| Other income (expense), net | -21 | - |
| Income tax expense | 6 | - |
| Net loss | -8,620 | -15,406 |
| Share-based compensation | 1,016 | 1,638 |
| Amortization of discounts on marketable securities | 249 | 441 |
| Non-cash lease expense | 21 | 40 |
| Depreciation | 18 | 14 |
| Amounts receivable | 99 | -75 |
| Prepaid expenses and other assets | -235 | 453 |
| Deposits | 0 | -1,108 |
| Accounts payable | 659 | 321 |
| Accrued liabilities and operating lease liabilities | 469 | -1,643 |
| Net cash used in operating activities | -6,550 | -14,747 |
| Purchase of marketable securities | 34,854 | 16,370 |
| Maturities and sales of marketable securities | 9,104 | 31,967 |
| Purchase of property and equipment | 16 | 18 |
| Net cash provided by (used in) investing activities | -25,766 | 15,579 |
| Proceeds from the sale of common shares, net of offering costs | 31,527 | 0 |
| Proceed from the exercise of common stock options | 465 | 257 |
| Deferred offering costs | 456 | - |
| Principal payments on finance lease obligations | 3 | 5 |
| Net cash provided by financing activities | 31,533 | 252 |
| Net increase (decrease) in cash and cash equivalents | -783 | 1,084 |
| Cash and cash equivalents at beginning of period | 3,025 | - |
| Cash and cash equivalents at end of period | 3,326 | - |
DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. (DMAC)